S65487 Solution for infusion 100 mg clinical trials

Phase I / II, open label, dose escalation part (phase I) followed by non-comparative expansion part (phase II), multi-centre study, evaluating safety, pharmacokinetics and efficacy of S65487, a Bcl2 inhibitor combined with azacitidine in adult patients with previously untreated acute myeloid leukemia not eligible for intensive treatment

This study is testing a new drug, S65487, with an existing drug, azacitidine, for adults with a type of blood cancer called Acute Myeloid Leukaemia (AML). It's for patients who haven't had treatment before and can't have intensive chemotherapy. We want to check if it's safe and how well it works.